AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.40 -1.88%

-$1.07 today

Market cap
$1.41B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.51M

Average 0.76M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$19.70M

FY 2025 · Annual

Investing Cash Flow

$228.03M

FY 2025 · Annual

+139.0% YoY

Financing Cash Flow

-$132.61M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.8M)(128.72M)(163.62M)(145.23M)49.61M
Depreciation & Amortization2.09M2.34M2.38M2.4M2.42M
Deferred Income Tax00000
Stock-Based Compensation15.35M27.36M33.21M34.05M36.07M
Change in Working Capital(7.49M)6.84M(324K)(66.33M)(80.73M)
Accounts Receivables(876K)(543K)(5.43M)(33.91M)6.92M
Inventory00000
Accounts Payables(4.74M)9.7M10.94M(33.84M)(87.33M)
Other Working Capital(1.87M)(2.32M)(5.83M)1.43M(313K)
Other Non-Cash Items1.93M18.6M7.56M39.77M12.31M
Operating Cash Flow(45.92M)(73.59M)(120.8M)(135.34M)19.7M
Capital Expenditures(1.37M)(358K)(807K)(358K)(87K)
Acquisitions (Net)0394.49M000
Purchases of Investments(118.66M)(802.5M)(303.92M)(380.38M)(196.41M)
Sales of Investments158.85M408.02M449.48M476.13M424.53M
Other Investing Activities15K(394.49M)000
Investing Cash Flow38.84M(394.85M)144.75M95.4M228.03M
Debt Repayment00(11.73M)34.77M(76.8M)
Common Stock Issued2.55M11.83M2.47M100.84M14.26M
Common Stock Repurchased00(50M)(456K)(68.63M)
Dividends Paid00000
Other Financing Activities249.75M32.19M(43K)(8.1M)(1.45M)
Financing Cash Flow252.3M44.02M(59.3M)127.05M(132.61M)
Effect of Forex Changes00000
Net Change in Cash245.21M(424.42M)(35.34M)87.12M115.12M
Free Cash Flow(47.29M)(73.95M)(121.61M)(135.7M)19.61M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$49.6M
+ D&A$2.4M
+ Stock-Based Comp$36.1M
+ Deferred Tax$0
- Working Capital-$80.7M
+ Other Non-Cash$12.3M
= Operating Cash Flow$19.7M
- Capex-$87.0K
= Free Cash Flow$19.6M

Analysis

FY2025 free cash flow is $19.6M. FCF conversion is 39.5% of net income. Operating cash flow was $19.7M, with capex of -$87.0K. The largest bridge item is Working Capital at -$80.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
4Statement of changes in beneficial ownershipOct 2, 2026
10-KT10-KT filingSep 21, 2026
8-KCurrent reportSep 21, 2026

Does ANAB generate free cash flow?

AnaptysBio, Inc. (ANAB) generated $19.61M of free cash flow in fiscal 2025.

How much operating cash flow does ANAB produce?

Operating cash flow was $19.70M, before capital expenditures of $87,000.00.